Epigenetic age shifts vary by tumor type across 20 solid cancers
In an abstract analyzing 1710 samples from 20 solid cancers, tumor tissue did not show uniform epigenetic age acceleration versus matched normal tissue; shifts differed by cancer type, and methylation events arose mainly through private subclonal branching. [1]
Automatic summary · not editorially reviewed
The key findings
DNA methylation age was estimated for 544 patients with matched normal and tumor samples using Horvath's epigenetic clock. [1]
Significant positive tumor-normal age differences appeared in endometrial, lung squamous, head and neck, and prostate cancers, and significant negative differences in renal and thyroid cancers. [1]
Methylation events arose predominantly through private, subclonal branching rather than early clonal events, and the X chromosome was overrepresented across nearly all solid cancers. [1]
The source at a glance
- Study type / format
- Abstract of a DNA methylation and phyloepigenetic analysis
- Population / context
- 1710 samples from 20 solid cancers in The Cancer Genome Atlas, including 544 patients with matched normal and tumor samples
- Summary based on
- Study abstract
- Publication status
- Preprint · peer-review status not confirmed
- Original publication
- August 3, 2026
Methylation clocks compared in matched tumor and normal tissue
The abstract describes integrating DNA methylation age estimation with phyloepigenetic reconstruction across 20 solid cancers, covering 1710 samples from The Cancer Genome Atlas. For 544 patients with matched normal and tumor samples, DNA methylation age was estimated using Horvath's epigenetic clock. Linear regression assessed correspondence to chronological age, and Wilcoxon signed-rank tests checked whether tumor-normal age differences deviated significantly from zero.
Supporting source [1]
Opposing age shifts by cancer type; subclonal methylation events
Applying the clock to normal tissue gave a mean absolute error of 17.6 years, substantially exceeding expectations. At cohort level, no ubiquitous acceleration emerged across all tumor types when tumor age was compared directly with matched normal tissue. Significant positive differences appeared in endometrial, lung squamous, head and neck, and prostate cancers; significant negative differences appeared in renal and thyroid cancers. Phyloepigenetic reconstruction showed methylation events arose predominantly through private, subclonal branching rather than early clonal events, and the X chromosome was overrepresented among methylation events across nearly all solid cancers.
Supporting source [1]
Abstract-only scope of the tumor methylation findings
The conclusion states that epigenetic aging in cancer is not uniform or consistently accelerated but reflects tissue-specific and often opposing patterns of change. The predominance of subclonal events is described as suggesting ongoing epigenetic diversification throughout tumor evolution, and the X-chromosome overrepresentation as indicating a distinct chromosome-level vulnerability. These are associations from an abstract; the full text was not reviewed, and the abstract does not report follow-up or clinical outcomes.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The abstract reports no follow-up or clinical outcomes, and the described patterns are associations, not causes.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Mukherji A, Chattopadhyay S. · europepmc.org · August 3, 2026